- Report
- October 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- August 2024
- 145 Pages
Global
From €2847EUR$2,999USD£2,402GBP
- Report
- June 2024
- 200 Pages
Global
From €7547EUR$7,950USD£6,366GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1424EUR$1,500USD£1,201GBP
- Report
- January 2022
- 60 Pages
Global
From €3750EUR$3,950USD£3,163GBP
- Report
- February 2024
- 138 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- January 2022
- 98 Pages
Global
From €3200EUR$3,611USD£2,794GBP
- Report
- July 2023
- 132 Pages
Global
From €902EUR$950USD£761GBP
- Report
- August 2022
- 321 Pages
Global
From €3389EUR$3,570USD£2,859GBP
Pressure ulcers, also known as bedsores, are localized areas of tissue damage caused by prolonged pressure on the skin. They are a common complication of immobility and are particularly common in elderly people and those with chronic illnesses. Treatment of pressure ulcers typically involves the use of topical medications, such as creams, ointments, and gels, as well as systemic medications, such as antibiotics and antifungals.
The pressure ulcers drug market is a subset of the larger dermatological drugs market. It includes a range of products designed to treat and prevent pressure ulcers, including topical medications, systemic medications, and dressings. These products are used in both inpatient and outpatient settings, and are typically prescribed by a physician.
The pressure ulcers drug market is highly competitive, with a number of large pharmaceutical companies competing for market share. Some of the major players in the market include Pfizer, Johnson & Johnson, Merck, Novartis, and GlaxoSmithKline. Show Less Read more